Annual EBITDA
-$173.63 M
-$136.60 M-368.90%
December 1, 2024
Summary
- As of March 14, 2025, SLNO annual EBITDA is -$173.63 million, with the most recent change of -$136.60 million (-368.90%) on December 1, 2024.
- During the last 3 years, SLNO annual EBITDA has fallen by -$143.34 million (-473.12%).
- SLNO annual EBITDA is now -21471.87% below its all-time high of -$804.90 thousand, reached on December 31, 2013.
Performance
SLNO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$49.48 M
+$29.36 M+37.24%
December 1, 2024
Summary
- As of March 14, 2025, SLNO quarterly EBITDA is -$49.48 million, with the most recent change of +$29.36 million (+37.24%) on December 1, 2024.
- Over the past year, SLNO quarterly EBITDA has stayed the same.
- SLNO quarterly EBITDA is now -2612.11% below its all-time high of $1.97 million, reached on March 31, 2013.
Performance
SLNO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$173.63 M
-$36.82 M-26.91%
December 1, 2024
Summary
- As of March 14, 2025, SLNO TTM EBITDA is -$173.63 million, with the most recent change of -$36.82 million (-26.91%) on December 1, 2024.
- Over the past year, SLNO TTM EBITDA has stayed the same.
- SLNO TTM EBITDA is now -8916.04% below its all-time high of $1.97 million, reached on March 31, 2013.
Performance
SLNO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SLNO EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -368.9% | 0.0% | 0.0% |
| 3 y3 years | -473.1% | -747.5% | -473.1% |
| 5 y5 years | -717.5% | -575.1% | -478.9% |
SLNO EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -685.6% | at low | -956.7% | +37.2% | -685.6% | at low |
| 5 y | 5-year | -717.5% | at low | -956.7% | +37.2% | -717.5% | at low |
| alltime | all time | <-9999.0% | at low | -2612.1% | +37.2% | -8916.0% | at low |
Soleno Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$173.63 M(+368.9%) | -$49.48 M(-37.2%) | -$173.63 M(+26.9%) |
| Sep 2024 | - | -$78.83 M(+246.7%) | -$136.81 M(+104.7%) |
| Jun 2024 | - | -$22.74 M(+0.7%) | -$66.85 M(+28.7%) |
| Mar 2024 | - | -$22.58 M(+78.4%) | -$51.93 M(+40.2%) |
| Dec 2023 | -$37.03 M(+67.5%) | -$12.66 M(+42.7%) | -$37.03 M(+27.5%) |
| Sep 2023 | - | -$8.87 M(+13.4%) | -$29.05 M(+12.6%) |
| Jun 2023 | - | -$7.82 M(+1.8%) | -$25.79 M(+9.1%) |
| Mar 2023 | - | -$7.68 M(+64.0%) | -$23.64 M(+7.0%) |
| Dec 2022 | -$22.10 M(-27.0%) | -$4.68 M(-16.6%) | -$22.10 M(-5.0%) |
| Sep 2022 | - | -$5.61 M(-1.1%) | -$23.26 M(-6.6%) |
| Jun 2022 | - | -$5.67 M(-7.6%) | -$24.89 M(-7.1%) |
| Mar 2022 | - | -$6.14 M(+5.2%) | -$26.78 M(-11.6%) |
| Dec 2021 | -$30.30 M(+1.0%) | -$5.84 M(-19.4%) | -$30.30 M(-4.7%) |
| Sep 2021 | - | -$7.24 M(-4.2%) | -$31.79 M(+2.1%) |
| Jun 2021 | - | -$7.56 M(-21.7%) | -$31.14 M(-1.0%) |
| Mar 2021 | - | -$9.65 M(+31.7%) | -$31.44 M(+4.8%) |
| Dec 2020 | -$30.00 M(+41.2%) | -$7.33 M(+11.1%) | -$30.00 M(+3.2%) |
| Sep 2020 | - | -$6.59 M(-16.1%) | -$29.06 M(+3.5%) |
| Jun 2020 | - | -$7.86 M(-4.2%) | -$28.08 M(+11.6%) |
| Mar 2020 | - | -$8.21 M(+28.5%) | -$25.16 M(+18.5%) |
| Dec 2019 | -$21.24 M(+80.4%) | -$6.39 M(+13.8%) | -$21.24 M(+18.5%) |
| Sep 2019 | - | -$5.62 M(+13.4%) | -$17.92 M(+15.9%) |
| Jun 2019 | - | -$4.95 M(+15.6%) | -$15.46 M(+14.5%) |
| Mar 2019 | - | -$4.28 M(+39.6%) | -$13.50 M(+14.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$11.77 M(+4.7%) | -$3.07 M(-2.9%) | -$11.77 M(-15.9%) |
| Sep 2018 | - | -$3.16 M(+5.7%) | -$14.00 M(+7.6%) |
| Jun 2018 | - | -$2.99 M(+17.0%) | -$13.01 M(+3.8%) |
| Mar 2018 | - | -$2.56 M(-51.8%) | -$12.54 M(+11.6%) |
| Dec 2017 | -$11.24 M(+35.3%) | -$5.30 M(+143.9%) | -$11.24 M(+44.9%) |
| Sep 2017 | - | -$2.17 M(-13.7%) | -$7.76 M(+2.7%) |
| Jun 2017 | - | -$2.52 M(+100.7%) | -$7.55 M(+3.4%) |
| Mar 2017 | - | -$1.25 M(-30.9%) | -$7.31 M(-29.0%) |
| Dec 2016 | -$8.31 M(-31.1%) | -$1.82 M(-7.8%) | -$10.30 M(+36.8%) |
| Sep 2016 | - | -$1.97 M(-13.3%) | -$7.53 M(-14.7%) |
| Jun 2016 | - | -$2.27 M(-46.5%) | -$8.83 M(-7.9%) |
| Mar 2016 | - | -$4.24 M(-545.5%) | -$9.58 M(+23.6%) |
| Dec 2015 | -$12.05 M(+32.7%) | $952.50 K(-129.2%) | -$7.75 M(-46.5%) |
| Sep 2015 | - | -$3.27 M(+7.8%) | -$14.49 M(+15.5%) |
| Jun 2015 | - | -$3.03 M(+25.6%) | -$12.54 M(+16.0%) |
| Mar 2015 | - | -$2.41 M(-58.3%) | -$10.81 M(+22.3%) |
| Dec 2014 | -$9.08 M(+1027.9%) | -$5.78 M(+339.2%) | -$8.84 M(+138.3%) |
| Sep 2014 | - | -$1.32 M(+1.3%) | -$3.71 M(+9.1%) |
| Jun 2014 | - | -$1.30 M(+196.1%) | -$3.40 M(+3.3%) |
| Mar 2014 | - | -$439.00 K(-32.9%) | -$3.29 M(+272.4%) |
| Dec 2013 | -$804.90 K(-77.5%) | -$653.90 K(-35.1%) | -$884.10 K(+284.1%) |
| Sep 2013 | - | -$1.01 M(-15.5%) | -$230.20 K(-129.6%) |
| Jun 2013 | - | -$1.19 M(-160.5%) | $777.10 K(-60.5%) |
| Mar 2013 | - | $1.97 M | $1.97 M |
| Dec 2012 | -$3.57 M | - | - |
FAQ
- What is Soleno Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Soleno Therapeutics?
- What is Soleno Therapeutics annual EBITDA year-on-year change?
- What is Soleno Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Soleno Therapeutics?
- What is Soleno Therapeutics quarterly EBITDA year-on-year change?
- What is Soleno Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Soleno Therapeutics?
- What is Soleno Therapeutics TTM EBITDA year-on-year change?
What is Soleno Therapeutics annual EBITDA?
The current annual EBITDA of SLNO is -$173.63 M
What is the all time high annual EBITDA for Soleno Therapeutics?
Soleno Therapeutics all-time high annual EBITDA is -$804.90 K
What is Soleno Therapeutics annual EBITDA year-on-year change?
Over the past year, SLNO annual EBITDA has changed by -$136.60 M (-368.90%)
What is Soleno Therapeutics quarterly EBITDA?
The current quarterly EBITDA of SLNO is -$49.48 M
What is the all time high quarterly EBITDA for Soleno Therapeutics?
Soleno Therapeutics all-time high quarterly EBITDA is $1.97 M
What is Soleno Therapeutics quarterly EBITDA year-on-year change?
Over the past year, SLNO quarterly EBITDA has changed by $0.00 (0.00%)
What is Soleno Therapeutics TTM EBITDA?
The current TTM EBITDA of SLNO is -$173.63 M
What is the all time high TTM EBITDA for Soleno Therapeutics?
Soleno Therapeutics all-time high TTM EBITDA is $1.97 M
What is Soleno Therapeutics TTM EBITDA year-on-year change?
Over the past year, SLNO TTM EBITDA has changed by $0.00 (0.00%)